氯沙坦钾对高血压左心室肥厚患者的临床效果及对血清中IGF-1影响的研究

Clinical effect of Cozaar in the treatment of patients with hypertension left ventricular hypertrophy and influence of Cozaar on serum IGF-1

目的:观察氯沙坦钾对高血压左心室肥厚患者的治疗作用及对血清中胰岛素样生长因子1(IGF-1)的影响,探讨其临床作用意义。方法:选取高血压左心室肥厚患者180例,随机分为观察组(90例)和对照组(90例),观察组应用氯沙坦钾治疗,对照组应用硝苯地平治疗,观察治疗前后舒张末期室间隔厚度(IVST)、舒张末期左室后壁厚度(LVPWT)和左心室重量指数(LVMI)的改变,同时观察治疗前后血清中IGF-1水平的变化,比较其差异。结果:观察组与对照组治疗后IVST[(45.35±6.75)mm,(47.68±5.42)mm]、LVPWT[(9.35±2.52)mm,(11.85±2.36)mm]和LVMI水平[(127.63±15.84)g/m2,(134.63±18.85)g/m2]均低于治疗前水平[观察组(48.65±6.86)mm、(13.04±2.53)mm、(156.75±14.74)g/m2;对照组(48.78±5.64)mm、(13.24±2.41)mm、(156.36±14.67)g/m2],差异有统计学意义(P<0.05);且观察组治疗前后IVST、LVPWT、LVMI的降低程度[(3.30±0.69)mm、(3.69±0.69)mm、(29.12±3.57)g/m2]明显高于对照组[(1.10±0.24)mm、(1.39±0.47)mm、(21.73±4.59)g/m2],差异有统计学意义(P<0.05)。观察组与对照组治疗后血清中IGF-1水平[(203.87±32.86)μg/L,(243.87±30.15)μg/L]明显低于治疗前[(284.74±45.21)μg/L,(282.86±34.84)μg/L],差异有统计学意义(P<0.05);且观察组治疗前后IGF-1的降低程度[(80.87±5.38)μg/L]明显高于对照组[(38.99±6.97)μg/L],差异有统计学意义(P<0.05)。结论:氯沙坦钾对高血压左心室肥厚患者的治疗作用明显,且可降低血清中IGF-1的表达,临床中可以积极应用。

Objective： To research the clinical effect of Cozaar on patients with hypertension left ventricular hypertrophy and influence of Cozaar on serum IGF-1, and discuss its clinical significance. Method： 180 cases of patients suffered from hypertension left ventricular hypertrophy were randomly divided into observation group and control group, each 90 cases. Observation group was given Cozaar, while control group was given Nifedipine, the alteration of IVST, LVPWT and LYMI were observed, and the level of serum IGF-1 was observed before and after treatment. Results： After treatment the level of IVST [（45.35±6.75） mm, （47.68±5.42） mm], LVPWT [（9.35±252） mm, （11.85±2.36） ram] and LVMI [（127.63±15.84） g/m2, （134.63±18.85） g/m2] decreased than that before treatment [observation group （48.65±6.86） mm, （13.04±2..53） mm, （156.75±14.74） g/m2 control group （48.78±5.64） mm, （13.24±2.41） mm, （156.36±14.67） g/m：] in observation group and control group, the difference was statistically significant （P〈0.05）; in observation group the decreasing degree of IVST, LVPWT, LVMI were higher than control group [observation group （3.30±069） mm, （3.69±0.69） ram, （29.12±3.57） g/m2, control group, （1.10±0.24） nun, （1.39±0.47） mm, （21.73±4.59） g/m2], the difference was statistically significant （P〈O.05）. In observation group and control group the level of IGF-1 [（203.87±32.86） p,g/L, （243.87±30.15） μg/L] after treatment decreased than that of before treatment [（284.74± 45.21） Ixg/L, （282.86±34.84） μg/L], the difference was statistically significant （P〈0.05）; in observation group the decreasing degree of IGF-1 was higher than control group [（80.87±5.38）μg/L, （38.99±6.97） μg/L], the difference was statistically significant （P〈0.05）. Conclusion： Cozaar has significant therapeutic action and can reduce the expression of serum IGF-1. It is worthy of clinical application.